8-K

Current Report

Adaptimmune Therapeutics PLC Filed 2021-09-07 Acc 0001558370-21-012236

Material agreement · Regulation FD disclosure · Other events

Item 1.01 Entry into a material definitive agreement
Item 7.01 Regulation FD disclosure
Item 8.01 Other events

From the SEC's structured data for this filing

Documents 1

8-K Current Report , adap-20210903x8k.htm

Around this filing

2021-09-13 8-K Other events
2021-09-07 8-K Material agreement · Regulation FD disclosure · Other events
2021-09-01 4 Chief Executive Officer sold 2,782 shares at $5.20 ($14,452)
2021-08-20 8-K Material agreement

Link to a passage

External